Quanterix (NASDAQ:QTRX) Stock Rating Upgraded by Wall Street Zen

Key Points

• Quanterix was upgraded by Wall Street Zen from “sell” to “hold”, although broader analyst sentiment remains cautious with a consensus rating of “Reduce” and an average price target of $4.00.
• The company reported better-than-expected EPS for the latest quarter at ($0.39) versus estimates of ($0.51), but revenue came in slightly below expectations at $35.90 million.
• QTRX shares were trading at $2.83, near their 52-week low of $2.56 and well below the 52-week high of $8.77, reflecting ongoing pressure on the stock.

Quanterix (NASDAQ:QTRX - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday.

QTRX has been the subject of several other research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Quanterix in a research note on Tuesday, April 21st. Canaccord Genuity Group decreased their target price on Quanterix from $8.00 to $4.00 and set a "hold" rating for the company in a research report on Monday, April 20th. Finally, TD Cowen decreased their target price on Quanterix from $7.00 to $4.00 and set a "hold" rating for the company in a research report on Thursday. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Reduce" and an average price target of $4.00.

Quanterix Stock Performance

Shares of QTRX stock opened at $2.83 on Friday. The firm has a market capitalization of $133.32 million, a P/E ratio of -1.20 and a beta of 1.15. Quanterix has a 52-week low of $2.56 and a 52-week high of $8.77. The stock has a 50 day moving average price of $4.11 and a 200 day moving average price of $5.60.

Quanterix (NASDAQ:QTRX - Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported ($0.39) EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.12. Quanterix had a negative net margin of 71.86% and a negative return on equity of 23.92%. The business had revenue of $35.90 million for the quarter, compared to analyst estimates of $36.84 million. As a group, sell-side analysts forecast that Quanterix will post -0.97 EPS for the current year.

Institutional Investors Weigh In On Quanterix

Institutional investors and hedge funds have recently bought and sold shares of the company. Farther Finance Advisors LLC bought a new stake in Quanterix during the 4th quarter valued at $26,000. Caitong International Asset Management Co. Ltd bought a new stake in Quanterix during the 4th quarter valued at $27,000. Quarry LP raised its position in shares of Quanterix by 277,300.0% in the 3rd quarter. Quarry LP now owns 5,548 shares of the company's stock worth $30,000 after acquiring an additional 5,546 shares in the last quarter. AXQ Capital LP bought a new position in shares of Quanterix in the 4th quarter worth $70,000. Finally, R Squared Ltd bought a new position in shares of Quanterix in the 3rd quarter worth $64,000. 86.48% of the stock is owned by institutional investors.

Quanterix Company Profile

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company's core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.